Dr. Ed Engleman: Vivo Capital’s Cancer Hacker
Dr. Ed Engleman of Vivo Capital makes a bold prediction that most cancers will be manageable or curable within twenty years, driven by an accelerating pace of medical discovery. The conversation explores how regulatory frameworks like orphan drug designations are shaping cancer treatment development and investment strategies in biotech.
Key takeaways
- •Cancer treatment breakthroughs are accelerating at an unprecedented pace, with most cancers expected to become manageable or curable within two decades.
- •Orphan drug designations for rare diseases create unique regulatory and commercial opportunities in cancer drug development.
- •The intersection of increasing discovery speed and targeted regulatory pathways is fundamentally reshaping cancer treatment timelines.
Listen to full episode
0:00
Two episodes. Free. Clips before your next meeting.
No card. No setup call. Paste your episode and see what Clypt surfaces.